Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Sampleswmm2022-12-29T21:22:21+00:00November 15th, 2022|2022 Publications, Featured Publications, Publications| Read more
Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testingwmm2023-01-16T21:30:16+00:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos| Watch video
High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancieswmm2023-01-16T21:27:56+00:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos| Watch video
NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determinationwmm2022-10-27T04:25:21+00:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos| Watch video
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AMLwmm2022-10-24T14:57:12+00:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patientswmm2022-12-29T21:19:31+00:00June 4th, 2022|2022 Publications, Featured Publications, Publications| Read more
Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?wmm2023-01-08T18:20:36+00:00May 30th, 2022|2022 Publications, Featured Publications, Publications| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-09T17:27:05+00:00May 9th, 2022|2022 Press Releases, Press Releases| Read more
Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patientswmm2022-01-06T05:38:03+00:00January 4th, 2022|2022 Publications, Featured Publications, Publications| Read more
NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLLwmm2022-01-08T23:37:03+00:00December 28th, 2021|2021 Publications, Publications| Read more
Plan for a Successful International Drug Approval with Early Development of the Accompanying CDxwmm2022-01-04T04:43:02+00:00December 8th, 2021|2021 Publications, Publications| Read more
Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platformwmm2022-01-30T21:35:17+00:00November 5th, 2021|2021 Publications, Publications| Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune Systemwmm2021-06-24T18:20:34+00:00June 24th, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and Chinawmm2021-06-03T20:36:18+00:00June 3rd, 2021|2021 Press Releases, Press Releases| Read more
Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphomawmm2023-01-10T16:48:18+00:00April 28th, 2021|2022 Publications, Featured Publications, Publications| Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2021-02-26T19:10:54+00:00January 3rd, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 Press Releases, Press Releases| Read more